Business
NetworkNewsWire Announces Publication Discussing Innovative Extraction Methods Used in the Production of Cannabinoids
New York, New York--(Newsfile Corp. - November 2, 2017) - NetworkNewsWire ("NNW"), a multifa...
About this update from Infield Minerals Corp
[{"type":"text","content":"NetworkNewsWire Announces Publication Discussing Innovative Extraction Methods Used in the Production of CannabinoidsNew York, New York--(Newsfile Corp. - November 2, 2017) - NetworkNewsWire (\"NNW\"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.The publication, titled, \"Economic Impact of Biosynthesis on the Cannabis Industry,\" discusses various innovative biotech companies aiming to produce cannabinoids while remaining both cost effective and consistent in quality. To view the full publication, visit: https://www.networknewswire.com/economic-impact-biosynthesis-cannabis-industry/ \"Meaningful economic impact on profits should easily accrue to cannabis companies capable of shedding all the costs and challenges associated with current cultivation to extraction methods. InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF)  is scientifically bypassing the horticultural approach to cannabinoid production by developing a robust, high-yield biosynthesis process. The company's proprietary cannabinoid manufacturing process combines the inherent safety and known efficacy of natural drug structures with the convenience, control and quality of a laboratory-based manufacturing process.\"Using its exclusive process in a controlled laboratory setting, InMed's scientists can create cannabinoid compounds that are identical to those found in nature without the difficult, expensive and time-consuming challenges of planting, growing and harvesting cannabis then laboriously extracting the individual cannabinoids for medical use. It also completely eliminates any need for fertilizers or pesticides. To protect this valuable asset, InMed recently filed a provisional patent for biosynthesis of cannabinoids. Once converted into an International Patent Cooperation Treaty (PCT) application, InMed will aggressively pursue key international jurisdictions.\"About InMed InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclin...